VRTX
VERTEX PHARMACEUTICALS INC / MAMarquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q3 2017 | 36Q | $149 | $437 | +194% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $468 | $437 | -7% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $471 | $437 | -7% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $471 | $437 | -7% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $471 | $437 | -7% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $471 | $437 | -7% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $471 | $437 | -7% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Maverick Capital 5× in & out | Q4 2023 | Q2 2024 | → $437 | +18% |
| Viking Global Investors | Q1 2015 | Q2 2016 | → $82 | -28% |
| Duquesne Family Office | Q4 2014 | Q1 2015 | → $110 | -2% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at VERTEX PHARMACEUTICALS INC / MA. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.
- Form 40000875320-26-000233Jun 9, 2026
- Form 40000875320-26-000230Jun 3, 2026
- Form 40000875320-26-000228Jun 2, 2026
- Form 40000875320-26-000226May 19, 2026
- Form 40000875320-26-000225May 19, 2026
- Form 40000875320-26-000222May 14, 2026
- Form 40000875320-26-000193May 5, 2026
- Form 40000875320-26-000191May 5, 2026
- Form 40000875320-26-000189May 5, 2026
- Form 40000875320-26-000187May 5, 2026
- Form 40000875320-26-000185May 5, 2026
- Form 40000875320-26-000183May 5, 2026
- Form 40000875320-26-000181May 5, 2026
- Form 40000875320-26-000179May 5, 2026
- Form 40000875320-26-000177May 5, 2026
Fundamentals
XBRL · VERTEX PHARMACEUTICALS INC / MAAnnual figures sourced directly from VERTEX PHARMACEUTICALS INC / MA's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for VERTEX PHARMACEUTICALS INC / MA — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 13, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 4, 2026
- 8-KMaterial eventApr 29, 2026
- DEF 14AProxy statementApr 2, 2026
- 8-KMaterial eventMar 31, 2026
- 10-KAnnual reportFeb 13, 2026
- 8-KMaterial eventFeb 12, 2026
- 10-QQuarterly reportNov 4, 2025
- 8-KMaterial eventNov 3, 2025
- 10-QQuarterly reportAug 5, 2025
- 8-KMaterial eventAug 4, 2025
- 8-KMaterial eventMay 19, 2025
- 8-KMaterial eventMay 14, 2025
- 10-QQuarterly reportMay 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $437 | $437 | -0% |
| Two Sigma Investments | Q1 2026 | open | $477 | $437 | -9% |
| Millennium Management | Q4 2025 | open | $437 | $437 | -0% |
| Bridgewater Associates | Q3 2025 | open | $396 | $425 | +7% |
| Citadel Advisors | Q3 2024 | open | $471 | $437 | -7% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $471 | $390 | -17% |
| D.E. Shaw | Q3 2024 | Q1 2026 | $471 | $477 | +1% |
| AQR Capital Management | Q3 2024 | open | $471 | $437 | -7% |
| Millennium Management | Q3 2024 | Q3 2025 | $471 | $390 | -17% |
| Renaissance Technologies | Q3 2024 | open | $468 | $437 | -7% |
| Maverick Capital | Q4 2023 | Q2 2024 | $370 | $437 | +18% |
| Maverick Capital | Q4 2021 | Q1 2022 | $187 | $231 | +24% |
| Maverick Capital | Q2 2021 | Q3 2021 | $216 | $191 | -12% |
| Bridgewater Associates | Q1 2021 | Q2 2025 | $214 | $421 | +97% |
| Maverick Capital | Q2 2020 | Q3 2020 | $289 | $267 | -7% |
| Bridgewater Associates | Q4 2019 | Q1 2020 | $207 | $240 | +16% |
| Bridgewater Associates | Q2 2019 | Q3 2019 | $167 | $184 | +10% |
| Bridgewater Associates | Q3 2018 | Q4 2018 | $175 | $170 | -3% |
| Bridgewater Associates | Q3 2017 | Q4 2017 | $149 | $148 | -0% |
| Maverick Capital | Q2 2015 | Q3 2015 | $126 | $137 | +8% |
| Viking Global Investors | Q1 2015 | Q2 2016 | $113 | $82 | -28% |
| Duquesne Family Office | Q4 2014 | Q1 2015 | $111 | $110 | -2% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.